You are here: Industry Insights > Molecular Partners

News List

Novartis and Molecular Partners report positive topline data from phase-II study for Ensovibep ExpressPharma
January 11, 2022
The secondary endpoint of hospitalisation and/or ER visits related to COVID-19, or death showed an overall 78 per cent reduction in risk of events across Ensovibep arms compared to placebo.
Novartis sets sights on potential COVID-19 antivirals from Molecular Partners pharmatimes
October 30, 2020
Swiss pharma company Novartis has inked an option and license agreement with Molecular Partners to develop, manufacture and commercialise the latter’s anti-COVID-19 DARPin programme.
AGC Biologics, Molecular Partners to Develop Anti-COVID-19 DARPin Program americanpharmaceuticalreview
July 20, 2020
AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin®.
AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program prnasia
July 09, 2020
Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Bio
Amgen and Molecular Partners to develop immune-oncology product pharmaceutical-technology
December 20, 2018
Amgen has collaborated with Swiss biopharmaceutical company Molecular Partners to develop and commercialise a pre-clinical immune-oncology candidate, MP0310....